{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:25:13Z","timestamp":1775593513027,"version":"3.50.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA15135"],"award-info":[{"award-number":["CA15135"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000028"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000028"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-029164"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029164"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/108119\/2015"],"award-info":[{"award-number":["SFRH\/BD\/108119\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/QUI\/00081"],"award-info":[{"award-number":["UID\/QUI\/00081"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejmech.2019.111572","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T02:05:38Z","timestamp":1564625138000},"page":"111572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease"],"prefix":"10.1016","volume":"181","author":[{"given":"Francesco","family":"Mesiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0437-358X","authenticated-orcid":false,"given":"Stefano","family":"Alcaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-2402","authenticated-orcid":false,"given":"Fernanda","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111572_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","article-title":"Current treatment options for Alzheimer's disease and Parkinson's disease dementia","volume":"14","author":"Szeto","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2019.111572_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1474-4422(16)30235-6","article-title":"Research priorities to reduce the global burden of dementia by 2025","volume":"15","author":"Shah","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2019.111572_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejmech.2019.111572_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejmech.2019.111572_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2019.111572_bib6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","article-title":"Converging pathways in neurodegeneration, from genetics to mechanisms","volume":"21","author":"Gan","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2019.111572_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-Directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2019.111572_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejmech.2014.01.060","article-title":"Multifunctional compounds: smart molecules for multifactorial diseases","volume":"76","author":"Bansal","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-017-0181-2","article-title":"A\u00a0perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2019.111572_bib11","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejmech.2019.111572_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4155\/fmc-2018-0249","article-title":"Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?","volume":"11","author":"Benchekroun","year":"2019","journal-title":"Future Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2019.111572_bib13","first-page":"587","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"15","author":"Zhou","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands - medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.111572_bib15","series-title":"Design of Hybrid Molecules for Drug Development","first-page":"259","article-title":"Medicinal chemistry of hybrids for neurodegenerative diseases","author":"Uliassi","year":"2017"},{"key":"10.1016\/j.ejmech.2019.111572_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41557-018-0021-z","article-title":"Organic synthesis provides opportunities to transform drug discovery","volume":"10","author":"Blakemore","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrd.2018.116","article-title":"Expanding the medicinal chemistry synthetic toolbox","volume":"17","author":"Bostr\u00f6m","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111572_bib18","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/acs.jmedchem.5b01409","article-title":"Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?","volume":"59","author":"Brown","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389557513666131119201353","article-title":"Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease","volume":"14","author":"Rodrigues Sim\u00f5es","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/17425255.1.3.527","article-title":"Donepezil: a review","volume":"1","author":"Seltzer","year":"2005","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2019.111572_bib21","author":"Reddy","year":"2004","journal-title":"US Pat. US 2004\/0143121 A1"},{"key":"10.1016\/j.ejmech.2019.111572_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ejmech.2017.02.043","article-title":"Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease","volume":"130","author":"Dias","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/cmdc.201600014","article-title":"Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer's disease","volume":"11","author":"Prati","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111572_bib24","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/slct.201600735","article-title":"8-Aminomethyl-7-hydroxy-4-methylcoumarins as multitarget leads for Alzheimer's disease","volume":"1","author":"Dom\u00ednguez","year":"2016","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2019.111572_bib25","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/acs.jmedchem.6b00426","article-title":"Benzylpiperidine-linked diarylthiazoles as potential anti-alzheimer's agents: synthesis and biological evaluation","volume":"59","author":"Shidore","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14756366.2016.1201814","article-title":"Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase\/monoamine oxidase inhibitors for the potential application against Alzheimer's disease","volume":"31","author":"Li","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib27","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1021\/acs.jmedchem.6b00562","article-title":"Exploring basic tail modifications of coumarin-based dual acetylcholinesterase-monoamine oxidase B inhibitors: identification of water-soluble, brain-permeant neuroprotective multitarget agents","volume":"59","author":"Pisani","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2017.02.039","article-title":"Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease","volume":"130","author":"Sang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/acschemneuro.8b00376","article-title":"Design, synthesis, and biological evaluation of dual-target inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 9A (PDE9A) for the treatment of Alzheimer's disease","volume":"10","author":"Hu","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.111572_bib30","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.bmc.2017.02.048","article-title":"Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer's disease based on the fusion of donepezil and curcumin","volume":"25","author":"Yan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2018.01.066","article-title":"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: discovery of novel multi-target anti-alzheimer prototype drug candidates","volume":"147","author":"Dias Viegas","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejmech.2017.04.054","article-title":"Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease","volume":"135","author":"Sang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cmdc.201500124","article-title":"Multitarget-directed tricyclic pyridazinones as G protein-coupled receptor ligands and cholinesterase inhibitors","volume":"10","author":"Pau","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111572_bib34","doi-asserted-by":"crossref","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","article-title":"Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment","volume":"111","author":"Lecoutey","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2019.111572_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11696-018-0590-8","article-title":"Tacrine hybrids as multi-target-directed ligands in Alzheimer's disease: influence of chemical structures on biological activities","volume":"73","author":"Girek","year":"2019","journal-title":"Chem. Pap."},{"key":"10.1016\/j.ejmech.2019.111572_bib36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.bmcl.2013.02.017","article-title":"Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease","volume":"23","author":"Romero","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111572_bib37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2174\/15680266113139990136","article-title":"Multifunctional tacrine derivatives in Alzheimer's disease","volume":"13","author":"Minarini","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib38","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2174\/092986707782023217","article-title":"Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment","volume":"14","author":"Musial","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejmech.2013.03.051","article-title":"Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease","volume":"64","author":"Xie","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jhet.5570440305","article-title":"Synthesis of tacrine derivatives under solventless conditions","volume":"44","author":"Khalilzadeh","year":"2007","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1039\/c0gc00953a","article-title":"Sulfuric acid-modified PEG-6000 (PEG-OSO3H): an efficient, bio-degradable and reusable polymeric catalyst for the solvent-free synthesis of poly-substituted quinolines under microwave irradiation","volume":"13","author":"Hasaninejad","year":"2011","journal-title":"Green Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib42","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/jm010308g","article-title":"Homodimeric tacrine congeners as acetylcholinesterase inhibitors","volume":"45","author":"Hu","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejmech.2018.09.008","article-title":"Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway","volume":"158","author":"Qin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","article-title":"Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-alzheimer\u2019s disease drug discovery","volume":"9","author":"Jiang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111572_bib45","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1007\/s00044-014-0931-2","article-title":"Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer's disease","volume":"23","author":"Hui","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111572_bib46","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1039\/C5MD00236B","article-title":"Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs","volume":"6","author":"Quintanova","year":"2015","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2019.111572_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ardp.201800050","article-title":"New tacrine-acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer's disease","volume":"351","author":"Chufarova","year":"2018","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2019.111572_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acs.jmedchem.5b01119","article-title":"Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography","volume":"59","author":"Zha","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib49","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1021\/jm5010804","article-title":"Multitarget drug design strategy: quinone\u2013tacrine hybrids designed to block Amyloid-\u03b2 aggregation and to exert anticholinesterase and antioxidant effects","volume":"57","author":"Nepovimova","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmech.2016.12.048","article-title":"Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease","volume":"127","author":"Jerabek","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejmech.2014.07.021","article-title":"Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies","volume":"84","author":"Di Pietro","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib52","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/molecules18022397","article-title":"7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment-synthesis, biological evaluation and molecular modeling studies","volume":"18","author":"Spilovska","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.111572_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2018.02.023","article-title":"Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease","volume":"148","author":"Hiremathad","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib54","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1021\/acschemneuro.8b00024","article-title":"Novel multitarget-directed ligands aiming at symptoms and causes of alzheimer's disease","volume":"9","author":"Wieckowska","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.111572_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/14756366.2017.1406485","article-title":"New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease","volume":"33","author":"Czarnecka","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib56","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cmdc.201500383","article-title":"Design, synthesis and in\u00a0vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer's disease","volume":"11","author":"Benek","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111572_bib57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejmech.2018.06.044","article-title":"Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease","volume":"155","author":"Chioua","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer's disease: an update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejmech.2019.111572_bib59","author":"Enz","year":"1988"},{"key":"10.1016\/j.ejmech.2019.111572_bib60","series-title":"Alzheimer's and Parkinson's Disease: Strategies for Research and Development","first-page":"539","article-title":"Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer's disease","author":"Weinstock","year":"1986"},{"key":"10.1016\/j.ejmech.2019.111572_bib61","author":"Weinstock Rosin","year":"1986"},{"key":"10.1016\/j.ejmech.2019.111572_bib62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/op3003147","article-title":"Industrial scale-up of enantioselective hydrogenation for the asymmetric synthesis of rivastigmine","volume":"17","author":"Yan","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2019.111572_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23092207","article-title":"Direct asymmetric reductive amination for the synthesis of (S)-Rivastigmine","volume":"23","author":"Gao","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.111572_bib64","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.tetasy.2013.01.023","article-title":"Asymmetric synthesis of an enantiomerically pure rivastigmine intermediate using ketoreductase","volume":"24","author":"Sethi","year":"2013","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.ejmech.2019.111572_bib65","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/bi020016x","article-title":"Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine","volume":"41","author":"Bar On","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111572_bib66","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/acs.jmedchem.6b00609","article-title":"Fatty acid amide hydrolase (FAAH), acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE): networked targets for the development of carbamates as potential anti-Alzheimer\u2019s disease agents","volume":"59","author":"Montanari","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bmc.2015.01.005","article-title":"Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease","volume":"23","author":"Sang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111572_bib68","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/j.bmc.2014.07.009","article-title":"Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy","volume":"22","author":"Li","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib69","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/acschemneuro.7b00268","article-title":"Discovery of novel pyrazolopyrimidinone derivatives as phosphodiesterase 9A inhibitors capable of inhibiting butyrylcholinesterase for treatment of alzheimer's disease","volume":"8","author":"Yu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.111572_bib70","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-170672","article-title":"Memantine for the treatment of dementia: a review on its current and future applications","volume":"62","author":"Folch","year":"2018","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.ejmech.2019.111572_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111572_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10242","article-title":"Elevated glucose and oligomeric beta-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation","volume":"7","author":"Akhtar","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.111572_bib73","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1517\/14656566.4.12.2305","article-title":"Evaluation of memantine for the treatment of Alzheimer's disease","volume":"4","author":"Ferris","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2019.111572_bib74","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","article-title":"Amantadine in the treatment of Parkinson's disease","volume":"208","author":"Schwab","year":"1969","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2019.111572_bib75","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd.2018.136","article-title":"Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs","volume":"17","author":"Charvin","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111572_bib76","author":"Gold","year":"2010"},{"key":"10.1016\/j.ejmech.2019.111572_bib77","author":"Reddy","year":"2011"},{"key":"10.1016\/j.ejmech.2019.111572_bib78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/op060246+","article-title":"An improved synthesis of memantine Hydrochloride:\u2009 anti-alzheimer's drug","volume":"11","author":"Reddy","year":"2007","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2019.111572_bib79","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1039\/C5SC02913A","article-title":"Pot economy and one-pot synthesis","volume":"7","author":"Hayashi","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2019.111572_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00304948.2017.1291004","article-title":"Convenient synthesis of memantine hydrochloride","volume":"49","author":"Ivleva","year":"2017","journal-title":"Org. Prep. Proced. Int."},{"key":"10.1016\/j.ejmech.2019.111572_bib81","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/ja01192a023","article-title":"A\u00a0new reaction of nitriles. II. Synthesis of t-carbinamines","volume":"70","author":"Ritter","year":"1948","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111572_bib82","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1021\/acs.oprd.7b00242","article-title":"An improved synthesis of amantadine hydrochloride","volume":"21","author":"Vu","year":"2017","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2019.111572_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep45627","article-title":"Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment","volume":"7","author":"Bachurin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.111572_bib84","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s11172-016-1461-5","article-title":"Molecular design of multitarget neuroprotectors 3. Synthesis and bioactivity of tetrahydrocarbazole\u2014aminoadamantane conjugates","volume":"65","author":"Sokolov","year":"2016","journal-title":"Russ. Chem. Bull."},{"key":"10.1016\/j.ejmech.2019.111572_bib85","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1021\/jm3009458","article-title":"Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease","volume":"55","author":"Simoni","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23010230","article-title":"Towards a novel class of multitarget-directed ligands: dual P2X7\u2013NMDA receptor antagonists","volume":"23","author":"Karoutzou","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.111572_bib87","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1021\/jm020120c","article-title":"Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease","volume":"45","author":"Sterling","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib88","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","article-title":"A\u00a0multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing","volume":"20","author":"Yogev-Falach","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2019.111572_bib89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-2010-100150","article-title":"Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation","volume":"21","author":"Bar Am","year":"2010","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.ejmech.2019.111572_bib90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4155\/fmc.15.12","article-title":"Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond","volume":"7","author":"Zindo","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib91","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1021\/jm020120c","article-title":"Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease","volume":"45","author":"Sterling","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib92","series-title":"US Pat. US 2006O199974A1","author":"Boulton","year":"2006"},{"key":"10.1016\/j.ejmech.2019.111572_bib93","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1016\/j.ejmech.2011.05.048","article-title":"Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease","volume":"46","author":"Samadi","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib94","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tetasy.2012.02.022","article-title":"An efficient and promising method to prepare Ladostigil (TV3326) via asymmetric transfer hydrogenation catalyzed by Ru\u2013Cs-DPEN in an HCOONa\u2013H2O\u2013surfactant system","volume":"23","author":"Luo","year":"2012","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.ejmech.2019.111572_bib95","first-page":"1893","article-title":"Multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids","volume":"8","author":"Bautista-Aguilera","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2019.111572_bib96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bmc.2010.11.040","article-title":"Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles","volume":"19","author":"Samadi","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib97","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1016\/j.bmc.2013.09.044","article-title":"1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases","volume":"21","author":"Koch","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib98","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer's agents","volume":"25","author":"Kosak","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2014.04.078","article-title":"Donepezil\u00a0+ propargylamine\u00a0+ 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease","volume":"80","author":"Wang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib100","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","article-title":"Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A\/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging","volume":"36","author":"Bar-Am","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2019.111572_bib101","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","article-title":"Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases","volume":"13","author":"Zheng","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111572_bib102","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ejmech.2017.07.008","article-title":"Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-beta aggregation for the treatment of Alzheimer's disease","volume":"138","author":"Yang","year":"2017","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419307020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419307020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:03:07Z","timestamp":1759327387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419307020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":102,"alternative-id":["S0223523419307020"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111572","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111572"}}